Sumanta K Pal1, Dean Bajorin2,3, Nazli Dizman1, Jean Hoffman-Censits4, David I Quinn5, Daniel P Petrylak6, Matthew D Galsky7, Ulka Vaishampayan8, Ugo De Giorgi9, Sumati Gupta10, Howard A Burris11, Harris S Soifer12, Gary Li12, Hao Wang13, Carl L Dambkowski14, Susan Moran15, Siamak Daneshmand16, Jonathan E Rosenberg17. 1. Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California. 2. Genitourinary Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Medicine, Weill Cornell Medical College, New York, New York. 4. Departments of Medical Oncology and Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. 5. University of Southern California Norris Comprehensive Cancer Center Keck School of Medicine at USC, Los Angeles, California. 6. Department of Medicine, Division of Oncology, Yale School of Medicine, New Haven, Connecticut. 7. Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, The Mount Sinai Hospital, New York, New York. 8. Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan. 9. Department of Medical Oncology, Scientific Institute of Romagna for the Study and Treatment of Cancer, IRCCS, Meldola, Italy. 10. Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. 11. Sarah Cannon Research Institute and Tennessee Oncology, Nashville, Tennessee. 12. Department of Translational Medicine, QED Therapeutics Inc, San Francisco, California. 13. Department of Biostatistics and Data Management, QED Therapeutics Inc, San Francisco, California. 14. Department of Strategy and Operations, QED Therapeutics Inc, San Francisco, California. 15. Department of Clinical Development, QED Therapeutics Inc, San Francisco, California. 16. Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California. 17. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: Infigratinib (BGJ398) is a potent and selective fibroblast grown factor receptor 1 to 3 (FGFR1-3) inhibitor with significant activity in patients with advanced or metastatic urothelial carcinoma bearing FGFR3 alterations. Given the distinct biologic characteristics of upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB), the authors examined whether infigratinib had varying activity in these settings. METHODS: Eligible patients had metastatic urothelial carcinoma with activating FGFR3 mutations and/or fusions. Comprehensive genomic profiling was performed on formalin-fixed, paraffin-embedded tissues. Blood was collected for cell-free DNA analysis using a 600-gene panel. Patients received infigratinib at a dose of 125 mg orally daily (3 weeks on/1 week off) until disease progression or intolerable toxicity occurred. The overall response rate (ORR; partial response [PR] plus complete response [CR]) and disease control rate (DCR; CR plus PR plus stable disease [SD]) were characterized. RESULTS: A total of 67 patients were enrolled; the majority (70.1%) had received ≥2 prior antineoplastic therapies. In 8 patients with UTUC, 1 CR and 3 PRs were observed (ORR, 50%); the remaining patients achieved a best response of SD (DCR, 100%). In patients with UCB, 13 PRs were observed (ORR, 22%), and 22 patients had a best response of SD (DCR, 59.3%). Notable differences in genomic alterations between patients with UTUC and those with UCB included higher frequencies of FGFR3-TACC3 fusions (12.5% vs 6.8%) and FGFR3 R248C mutations (50% vs 11.9%), and a lower frequency of FGFR3 S249C mutations (37.5% vs 59.3%). CONCLUSIONS: Differences in the cumulative genomic profile were observed between patients with UTUC and those with UCB in the current FGFR3-restricted experience, underscoring the distinct biology of these diseases. These results support a planned phase 3 adjuvant study predominantly performed in this population.
BACKGROUND:Infigratinib (BGJ398) is a potent and selective fibroblast grown factor receptor 1 to 3 (FGFR1-3) inhibitor with significant activity in patients with advanced or metastatic urothelial carcinoma bearing FGFR3 alterations. Given the distinct biologic characteristics of upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB), the authors examined whether infigratinib had varying activity in these settings. METHODS: Eligible patients had metastatic urothelial carcinoma with activating FGFR3 mutations and/or fusions. Comprehensive genomic profiling was performed on formalin-fixed, paraffin-embedded tissues. Blood was collected for cell-free DNA analysis using a 600-gene panel. Patients received infigratinib at a dose of 125 mg orally daily (3 weeks on/1 week off) until disease progression or intolerable toxicity occurred. The overall response rate (ORR; partial response [PR] plus complete response [CR]) and disease control rate (DCR; CR plus PR plus stable disease [SD]) were characterized. RESULTS: A total of 67 patients were enrolled; the majority (70.1%) had received ≥2 prior antineoplastic therapies. In 8 patients with UTUC, 1 CR and 3 PRs were observed (ORR, 50%); the remaining patients achieved a best response of SD (DCR, 100%). In patients with UCB, 13 PRs were observed (ORR, 22%), and 22 patients had a best response of SD (DCR, 59.3%). Notable differences in genomic alterations between patients with UTUC and those with UCB included higher frequencies of FGFR3-TACC3 fusions (12.5% vs 6.8%) and FGFR3R248C mutations (50% vs 11.9%), and a lower frequency of FGFR3S249C mutations (37.5% vs 59.3%). CONCLUSIONS: Differences in the cumulative genomic profile were observed between patients with UTUC and those with UCB in the current FGFR3-restricted experience, underscoring the distinct biology of these diseases. These results support a planned phase 3 adjuvant study predominantly performed in this population.
Authors: Jeffrey S Ross; Kai Wang; Depinder Khaira; Siraj M Ali; Huge A G Fisher; Badar Mian; Tipu Nazeer; Julia A Elvin; Norma Palma; Roman Yelensky; Doron Lipson; Vincent A Miller; Philip J Stephens; Vivek Subbiah; Sumanta K Pal Journal: Cancer Date: 2015-12-09 Impact factor: 6.860
Authors: Sumanta K Pal; Jonathan E Rosenberg; Jean H Hoffman-Censits; Raanan Berger; David I Quinn; Matthew D Galsky; Juergen Wolf; Christian Dittrich; Bhumsuk Keam; Jean-Pierre Delord; Jan H M Schellens; Gwenaelle Gravis; Jacques Medioni; Pablo Maroto; Virote Sriuranpong; Chaiyut Charoentum; Howard A Burris; Viktor Grünwald; Daniel Petrylak; Ulka Vaishampayan; Eliahu Gez; Ugo De Giorgi; Jae-Lyun Lee; Jens Voortman; Sumati Gupta; Sunil Sharma; Amir Mortazavi; David J Vaughn; Randi Isaacs; Katie Parker; Xueying Chen; Kun Yu; Dale Porter; Diana Graus Porta; Dean F Bajorin Journal: Cancer Discov Date: 2018-05-30 Impact factor: 39.397
Authors: Timothy P S Perera; Eleonora Jovcheva; Laurence Mevellec; Jorge Vialard; Desiree De Lange; Tinne Verhulst; Caroline Paulussen; Kelly Van De Ven; Peter King; Eddy Freyne; David C Rees; Matthew Squires; Gordon Saxty; Martin Page; Christopher W Murray; Ron Gilissen; George Ward; Neil T Thompson; David R Newell; Na Cheng; Liang Xie; Jennifer Yang; Suso J Platero; Jayaprakash D Karkera; Christopher Moy; Patrick Angibaud; Sylvie Laquerre; Matthew V Lorenzi Journal: Mol Cancer Ther Date: 2017-03-24 Impact factor: 6.261
Authors: Lucia Nogova; Lecia V Sequist; Jose Manuel Perez Garcia; Fabrice Andre; Jean-Pierre Delord; Manuel Hidalgo; Jan H M Schellens; Philippe A Cassier; D Ross Camidge; Martin Schuler; Ulka Vaishampayan; Howard Burris; G Gary Tian; Mario Campone; Zev A Wainberg; Wan-Teck Lim; Patricia LoRusso; Geoffrey I Shapiro; Katie Parker; Xueying Chen; Somesh Choudhury; Francois Ringeisen; Diana Graus-Porta; Dale Porter; Randi Isaacs; Reinhard Buettner; Jürgen Wolf Journal: J Clin Oncol Date: 2016-11-21 Impact factor: 44.544
Authors: François Audenet; Sumit Isharwal; Eugene K Cha; Mark T A Donoghue; Esther N Drill; Irina Ostrovnaya; Eugene J Pietzak; John P Sfakianos; Aditya Bagrodia; Paari Murugan; Guido Dalbagni; Timothy F Donahue; Jonathan E Rosenberg; Dean F Bajorin; Maria E Arcila; Jaclyn F Hechtman; Michael F Berger; Barry S Taylor; Hikmat Al-Ahmadie; Gopa Iyer; Bernard H Bochner; Jonathan A Coleman; David B Solit Journal: Clin Cancer Res Date: 2018-10-23 Impact factor: 12.531
Authors: Yohann Loriot; Andrea Necchi; Se Hoon Park; Jesus Garcia-Donas; Robert Huddart; Earle Burgess; Mark Fleming; Arash Rezazadeh; Begoña Mellado; Sergey Varlamov; Monika Joshi; Ignacio Duran; Scott T Tagawa; Yousef Zakharia; Bob Zhong; Kim Stuyckens; Ademi Santiago-Walker; Peter De Porre; Anne O'Hagan; Anjali Avadhani; Arlene O Siefker-Radtke Journal: N Engl J Med Date: 2019-07-25 Impact factor: 91.245
Authors: Manish R Patel; John Ellerton; Jeffrey R Infante; Manish Agrawal; Michael Gordon; Raid Aljumaily; Carolyn D Britten; Luc Dirix; Keun-Wook Lee; Mathew Taylor; Patrick Schöffski; Ding Wang; Alain Ravaud; Arnold B Gelb; Junyuan Xiong; Galit Rosen; James L Gulley; Andrea B Apolo Journal: Lancet Oncol Date: 2017-12-05 Impact factor: 41.316
Authors: John G Tate; Sally Bamford; Harry C Jubb; Zbyslaw Sondka; David M Beare; Nidhi Bindal; Harry Boutselakis; Charlotte G Cole; Celestino Creatore; Elisabeth Dawson; Peter Fish; Bhavana Harsha; Charlie Hathaway; Steve C Jupe; Chai Yin Kok; Kate Noble; Laura Ponting; Christopher C Ramshaw; Claire E Rye; Helen E Speedy; Ray Stefancsik; Sam L Thompson; Shicai Wang; Sari Ward; Peter J Campbell; Simon A Forbes Journal: Nucleic Acids Res Date: 2019-01-08 Impact factor: 16.971
Authors: Mathijs P Scholtes; Arnout R Alberts; Iris G Iflé; Paul C M S Verhagen; Astrid A M van der Veldt; Tahlita C M Zuiverloon Journal: Int J Mol Sci Date: 2021-03-11 Impact factor: 5.923
Authors: Yung Lyou; Jonathan E Rosenberg; Jean Hoffman-Censits; David I Quinn; Daniel Petrylak; Matthew Galsky; Ulka Vaishampayan; Ugo De Giorgi; Sumati Gupta; Howard Burris; Jessica Rearden; Ai Li; Cindy Xu; Corina Andresen; Susan Moran; Siamak Daneshmand; Dean Bajorin; Sumanta K Pal; Petros Grivas Journal: Clin Genitourin Cancer Date: 2021-10-13 Impact factor: 3.121